Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku - BioSpace
  Nippon Shinyaku to pay $36M to reserve US rights to AB2 Bio's near-approval autoimmune drug - Fierce Biotech
  Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - Pharmaceutical Technology
  Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive
  Nippon Shinyaku Co FY Net Y32.56B Vs Net Y25.85B - MarketWatch
  $810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership - geneonline.com
  Nippon Shinyaku and Atsena Therapeutics enter into an - GlobeNewswire
  AB2 Bio, Nippon Shinyaku in $686M deal for IL-18 drug tadekinig - BioWorld MedTech